On May 18, 2018 BerGenBio ASA (OSE: BGBIO) reported that the company and its collaborators will present interim clinical data from its Phase II clinical development programme with bemcentinib, a selective, oral AXL inhibitor, in acute myeloid leukaemia (AML) and myeloid dysplastic syndrome (MDS) at the 23rd Congress of the European Hematology Association (EHA) (Free EHA Whitepaper) in Stockholm (14-17 June 2018) (Press release, BerGenBio, MAY 18, 2018, View Source [SID1234526793]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstracts are now available online at View Source and details of the presentations are below. The posters presented at EHA (Free EHA Whitepaper) will be made available on www.bergenbio.com in the Investors / Presentations section following the sessions.

Presentations at EHA (Free EHA Whitepaper)
Saturday 16 June, 5:30 – 7:00 PM CEST

Ph II trial with selective oral AXL inhibitor bemcentinib (BGB324) in relapsed/refractory AML and MDS: Identification of predictive and pharmacodynamic biomarker candidates associated with pt benefit

Sonja Loges, MD, PhD et al
Session: Acute myeloid leukemia – Clinical
Poster Board: PS981
Single cell signaling pharmacodynamics and clonal evolution in a phase I/II clinical trial of selective AXL inhibitor bemcentinib (BGB324) in R/R acute myeloid leukemia and myelodysplastic syndrome

Monica Hellesøy, PhD et al
Session: Acute myeloid leukemia – Biology & Translational Research
Poster Board: PS965